MK-7(45μg/日)可改善绝经后女性骨密度(Rønn et al., Osteoporos Int 2016)
心血管保护
抑制血管钙化(通过基质Gla蛋白激活)
降低动脉僵硬度(Knapen et al., Thromb Haemost 2015)
三、使用禁忌与注意事项
副作用
口服:恶心、味觉异常(MK-7发生率<3%)
注射:面部潮红(与吐温-80溶剂相关)
超剂量(>5mg):溶血性贫血风险
禁忌与风险
华法林治疗期间禁用高剂量补充(干扰INR值)
严重肝功能不全者需调整剂量
与考来烯胺等胆汁酸螯合剂存在相互作用
苯妥英钠长期使用会加速MK-4代谢
参考文献
Shearer MJ, Newman P. Metabolism and cell biology of vitamin K. Thromb Haemost. 2008;100(4):530-47.
Theuwissen E, et al. Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects. Br J Nutr. 2012;108(9):1652-7.
Sato T, et al. Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. Nutr J. 2012;11:93.
FDA Professional Drug Information: Phytonadione (Vitamin K1) Injection.